Not all sufferers with CLL have to have therapy. Despite all the latest innovations, the iwCLL continue to suggests watchful observation for clients with asymptomatic illness.86 This advice relies on no less than two randomized trials evaluating observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,10